PT1409021E - Formulation comprising fulvestrant - Google Patents

Formulation comprising fulvestrant Download PDF

Info

Publication number
PT1409021E
PT1409021E PT02745579T PT02745579T PT1409021E PT 1409021 E PT1409021 E PT 1409021E PT 02745579 T PT02745579 T PT 02745579T PT 02745579 T PT02745579 T PT 02745579T PT 1409021 E PT1409021 E PT 1409021E
Authority
PT
Portugal
Prior art keywords
formulation
fulvestrant
oestra
17beta
triene
Prior art date
Application number
PT02745579T
Other languages
Portuguese (pt)
Inventor
Paul Richard Gellert
Alison Margaret Potts
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1409021E publication Critical patent/PT1409021E/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to a pharmaceutical formulation, preferably adapted for administration by injection, containing the compound 7a-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol and an antioxidant, more particularly to a formulation adapted for administration by injection containing the compound 7a-[9-(4,4,5,5,5-pentafluoropentyl-sulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol in solution in a ricinoleate vehicle which comprises an antioxidant.
PT02745579T 2001-07-07 2002-07-03 Formulation comprising fulvestrant PT1409021E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0116620.6A GB0116620D0 (en) 2001-07-07 2001-07-07 Formulation

Publications (1)

Publication Number Publication Date
PT1409021E true PT1409021E (en) 2008-01-11

Family

ID=9918096

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02745579T PT1409021E (en) 2001-07-07 2002-07-03 Formulation comprising fulvestrant

Country Status (12)

Country Link
US (1) US20040175402A1 (en)
EP (1) EP1409021B1 (en)
JP (1) JP4295087B2 (en)
AT (1) ATE378070T1 (en)
AU (1) AU2002317298A1 (en)
CY (1) CY1107142T1 (en)
DE (1) DE60223542T2 (en)
DK (1) DK1409021T3 (en)
ES (1) ES2294146T3 (en)
GB (1) GB0116620D0 (en)
PT (1) PT1409021E (en)
WO (1) WO2003006063A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112837A1 (en) * 2003-05-23 2004-12-29 Hisamitsu Pharmaceutical Co., Inc. PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1α PRODUCTION INHIBITOR
JP5133064B2 (en) * 2005-01-05 2013-01-30 國防教育研究基金会 Inhibitors and promoters of uridine diphosphate (UDP) -glucuronyltransferase 2B (UGT2B)
WO2007033434A1 (en) * 2005-09-26 2007-03-29 Hospira Australia Pty Ltd Fulvestrant formulation
KR20070088695A (en) * 2005-10-05 2007-08-29 시코르, 인크. Separation of fulvestrant isomers
KR20100121505A (en) 2008-03-07 2010-11-17 싸이도우스 엘엘씨. Fulvestrant formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US9029582B2 (en) 2011-05-20 2015-05-12 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102600064A (en) * 2012-03-31 2012-07-25 西安力邦制药有限公司 Fulvestrant or fulvestrant derivative sustained release preparation and preparation method thereof
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2015157752A1 (en) * 2014-04-11 2015-10-15 Sam Houston State University Dialkyl trisulfides and formulations of dialkyl trisulfides for use as a cyanide antidote
CN108159055A (en) * 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 Treat long-acting delivery system, preparation method and the application of breast cancer
WO2019151353A1 (en) * 2018-01-31 2019-08-08 富士フイルム株式会社 Method for producing preparation for injection
CN113694017B (en) * 2020-05-11 2024-04-02 鲁南制药集团股份有限公司 Fulvestrant injection preparation and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
WO2003006063A3 (en) 2003-05-15
EP1409021B1 (en) 2007-11-14
AU2002317298A1 (en) 2003-01-29
ES2294146T3 (en) 2008-04-01
JP4295087B2 (en) 2009-07-15
US20040175402A1 (en) 2004-09-09
EP1409021A2 (en) 2004-04-21
DK1409021T3 (en) 2008-02-11
DE60223542D1 (en) 2007-12-27
JP2004521151A (en) 2004-07-15
WO2003006063A2 (en) 2003-01-23
GB0116620D0 (en) 2001-08-29
DE60223542T2 (en) 2008-11-13
ATE378070T1 (en) 2007-11-15
CY1107142T1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
CY1107142T1 (en) STANDARDIZATION INCLUDING FULVESTRANT
BG106833A (en) Fulvestrant formulation
WO2004093795A3 (en) Compositions for delivery of drug combinations
NZ527157A (en) Compositions for delivering bisphosphonates
HK1065714A1 (en) Compositions for delivery of drug combinations
WO1999053910A8 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
PT1299348E (en) Compounds and compositions for delivering active agents
HK1077208A1 (en) Topical composition containing at least one vitminD or one vitamin D analogue and at least one cort icosteroid
EP1040823A3 (en) Stable foam compositions
AU2001260455A1 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
HK1084941A1 (en) Compounds and their use
MXPA05008913A (en) Stable ophthalmic formulation containing an antibiotic and a corticosteroid.
IL166432A0 (en) Composition containing an androgenous 11?-halogen steroid and a progestational hormone and male contraceptive based on said composition
MXPA03007857A (en) Compounds and compositions for delivering active agents.
CA2347195A1 (en) Oral pharmaceutical compositions containing buprenorphin
WO2002015959A3 (en) Compounds and compositions for delivering active agents
IL151910A0 (en) Compositions for drug delivery
MY132911A (en) Clear, injectable solution of an anesthetic compound
MXPA04000028A (en) Pharmaceutical formulation for the intramuscular administration of fulvestrant.
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AU2624499A (en) Oral compositions at low dosage of cytotoxic proteins
EP1232740A3 (en) Hair-growing agent
GB0128071D0 (en) Medicament